Kidney Cancer Weekly

June 01, 2026

Videos

Peer-to-Peer Clinical Conversations

A Phase II Trial of VEGFR-TKI Plus PD-1 Inhibitor in Non-Clear Cell Renal Carcinoma - Jiwei Huang

Jiwei Huang

Jiwei Huang presents phase 2 data on fruquintinib plus serplulimab as first-line therapy for metastatic non-clear cell renal cell carcinoma.

Whole-Genome Sequencing-Based MRD Detection Under Study in Resectable Renal Cell Carcinoma - Taigo Kato

Taigo Kato discusses a longitudinal ctDNA study in renal cell carcinoma patients undergoing radical nephrectomy.

Beyond the Abstracts

Impact of Brain Metastases on Systemic Renal Cell Carcinoma Treatment Outcomes: A Systematic Literature Review - Beyond the Abstract

Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma-An Observational Prospective Multicentre Diagnostic Test Cohort Study - Beyond the Abstract

Conference Coverage

ASCO 2026: Decision Regret and Toxicity Perception Following Adjuvant Immune Checkpoint Inhibitor in Renal Cell Carcinoma

ASCO 2026: Durvalumab Monotherapy Versus Active Monitoring for Resected Primary RCC in RAMPART: An International, Phase 3, Randomized Controlled Trial

ASCO 2026: A Prospective, Multi-Center, Phase 1b/II Trial of First-Line Cadonilimab + Axitinib in Advanced Non-Clear Cell RCC

ASCO 2026: ctDNA Analysis in Participants with RCC Treated with Adjuvant Pembrolizumab in the KEYNOTE-564 Trial

ASCO 2026: A Phase 2 Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with RCC with Bone Metastases: RADICAL (Alliance A031801)

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma.

Sex-Specific Adverse Events and Cardiovascular Toxicity of Cabozantinib in Renal Cell Carcinoma: A Nine-Year Pharmacovigilance Study.

Joint effects and dynamic trajectories of metabolic insulin resistance and systemic inflammation in the risk of renal cell carcinoma: a UK Biobank cohort analysis.

Natural Products in Clear Cell Renal Cell Carcinoma: Rewiring the VHL-HIF Axis, Metabolic Plasticity, and Tumor-Immune Interactions.

Metastatic Patterns and Adverse Histopathologic Features in Advanced Renal Cell Carcinoma: A Five-Year Single-Center Retrospective Pathology Study.

Histologic Heterogeneity of Metastases in Clear Cell Renal Cell Carcinoma with Sarcomatoid Differentiation.

Overdiagnosis in renal cancer: the hidden consequence of modern imaging.

Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial.

Improving Clear Cell Renal Cell Carcinoma Diagnosis: Modified CT Algorithms with Simplified Heterogeneity Scoring.

Two decades of research on drug resistance in renal cell carcinoma.

CONNECT WITH US

Questions or Comments? Email us at

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC